A Phase II/III, Double-blind, Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy of RUTI® to Reduce the Severity of SARS-CoV-2 Infection
Latest Information Update: 16 Feb 2023
At a glance
- Drugs Tuberculosis-vaccine-Archivel-Farma (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Sponsors RUTI Immunotherapeutics
- 08 Feb 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 15 Nov 2021 New trial record